Compositions for regulating gastric acid buildup using cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabicyclol (“CBL”), cannabichromene (“CBC”), cannabidivarin (“CBDV”), cannabidol (“CBD”), cannabigerol hexyl (“CBG-C6”), cannabigerol heptyl (“CBG-C7”), cannabigerol nonyl (“CBG-C9”), cannabidol-C2 (“CBD-C2”), cannabidol hexyl (“CBD-C6”), and cannabidol heptyl (“CBD-C7”). The cannabinoid compounds can be H.sub.2 antagonists. Methods and articles including the cannabinoid compounds are further disclosed.

Compositions for regulating gastric acid buildup using cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabicyclol (“CBL”), cannabichromene (“CBC”), cannabidivarin (“CBDV”), cannabidol (“CBD”), cannabigerol hexyl (“CBG-C6”), cannabigerol heptyl (“CBG-C7”), cannabigerol nonyl (“CBG-C9”), cannabidol-C2 (“CBD-C2”), cannabidol hexyl (“CBD-C6”), and cannabidol heptyl (“CBD-C7”). The cannabinoid compounds can be H.sub.2 antagonists. Methods and articles including the cannabinoid compounds are further disclosed.

Compositions and methods for preventing or relieving hangover symptoms are provided. The composition comprises a flavonoid such as dihydromyricetin, an antioxidant comprising a substituted pyridine, such as emoxypine succinate, and a mononucleotide such as nicotinamide mononucleotide. The composition may be administered to a subject in need thereof as an oral formulation.

Compositions and methods for preventing or relieving hangover symptoms are provided. The composition comprises a flavonoid such as dihydromyricetin, an antioxidant comprising a substituted pyridine, such as emoxypine succinate, and a mononucleotide such as nicotinamide mononucleotide. The composition may be administered to a subject in need thereof as an oral formulation.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

The present invention relates to a cannabinoid containing oral solution. Preferably the cannabinoid is cannabidiol (CBD), cannabidivarin (CBDV) or cannabidiol-C4 (CBD-C4). More preferably the CBD, CBDV or CBD-C4 is present at a concentration of between 25 and 75 mg/ml. More preferably still the CBD, CBDV or CBD-C4 is present at a concentration of 50 mg/ml. In a further embodiment the oral solution is formulated with one or more edible oils. Preferably the edible oil is sesame oil. It is a preferred embodiment of the invention that the oral formulation comprises a low concentration of ethanol.

The present invention relates to a cannabinoid containing oral solution. Preferably the cannabinoid is cannabidiol (CBD), cannabidivarin (CBDV) or cannabidiol-C4 (CBD-C4). More preferably the CBD, CBDV or CBD-C4 is present at a concentration of between 25 and 75 mg/ml. More preferably still the CBD, CBDV or CBD-C4 is present at a concentration of 50 mg/ml. In a further embodiment the oral solution is formulated with one or more edible oils. Preferably the edible oil is sesame oil. It is a preferred embodiment of the invention that the oral formulation comprises a low concentration of ethanol.

N-(furan-2-ylmethyl)-7H-purin-6-amine, or a pharmaceutically acceptable salt or solvate thereof, for prevention and/or treatment of circadian rhythm disorders, circadian rhythm diseases and/or circadian rhythm dysfunctions is disclosed. The disorders, diseases and dysfunctions include, inter alia, jet-lag, social jet-lag, shift-work disorder, and circadian rhythm disturbance induced by neurodegeneration is also disclosed.